InVitae (NYSE:NVTA) issued its quarterly earnings results on Monday. The medical research company reported ($0.78) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.61) by ($0.17), Briefing.com reports. The business had revenue of $25.40 million during the quarter, compared to the consensus estimate of $24.18 million. InVitae had a negative return on equity of 115.25% and a negative net margin of 206.95%. The business’s quarterly revenue was up 175.0% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.69) earnings per share.
InVitae (NVTA) traded down $0.75 on Tuesday, hitting $5.54. The stock had a trading volume of 1,136,803 shares, compared to its average volume of 1,021,106. The company has a market capitalization of $333.03 and a PE ratio of -2.26. The company has a current ratio of 2.61, a quick ratio of 2.61 and a debt-to-equity ratio of 0.33. InVitae has a 1-year low of $3.80 and a 1-year high of $10.41.
Several research analysts have commented on NVTA shares. Ladenburg Thalmann Financial Services started coverage on InVitae in a research report on Friday, January 5th. They issued a “buy” rating and a $15.00 price target on the stock. Leerink Swann dropped their price target on InVitae from $12.00 to $10.00 and set an “outperform” rating on the stock in a research report on Tuesday, January 16th. Zacks Investment Research downgraded InVitae from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, October 17th. Benchmark dropped their price target on InVitae from $16.00 to $11.00 and set a “buy” rating on the stock in a research report on Tuesday, January 16th. Finally, BidaskClub downgraded InVitae from a “sell” rating to a “strong sell” rating in a research report on Wednesday, November 15th. Three analysts have rated the stock with a sell rating and four have assigned a buy rating to the stock. InVitae presently has a consensus rating of “Hold” and a consensus price target of $11.00.
Invitae Corporation utilizes an integrated portfolio of laboratory processes, software tools and informatics capabilities to process deoxyribonucleic acid (DNA)-containing samples, analyze information about patient-specific genetic variation and generate test reports for clinicians and their patients.
Receive News & Ratings for InVitae Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for InVitae and related companies with MarketBeat.com's FREE daily email newsletter.